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Abstract: The combination of more than one pharmacophore in a mulitargeted anticancer agent may result in synergistic activity 
of its components. Using this concept, bioorganometallic compounds were designed to feature a metal center, a 2-
pyridinecarbothioamide (PCA), and a hydroxamic acid, which is found in the anticancer drug vorinostat (SAHA). The 
organometallics showed inhibitory activity in the nanomolar range against histone deacetylases (HDACs) as the key target for 
SAHA. In particular, Rh complex 4c was a potent inhibitor of HDAC6 over HDAC1 and HDAC8. While especially 4c was highly 
cytotoxic in human cancer cells, it showed low toxicity in hemolysis studies and zebrafish, demonstrating the role of the metal 
center. The impact of the PCA moiety was established in the reduced expression of VEGFR2, which is upregulated by SAHA. 
This indicates that the new organometallics display different modes of action than its components, supporting the development 
of non-conventional anticancer drugs.  
 
Histone deacetylases (HDACs) are overexpressed in solid tumor malignancies and in hematological cancers, leading to 
poor prognosis.[1] The upregulation of HDACs is known to induce tumor angiogenesis related to hypoxia. [2] The inhibition 
of HDACs using small molecules is an important therapeutic strategy in anticancer drug discovery, which has been 
validated by the FDA approval of vorinostat (suberoylanilide hydroxamic acid, SAHA) [3] and romidepsin (FK-228) for 
clinical use, both of which target the ZnII ion of HDACs.[4] Moreover, modulation of the activity of HDACs can change the 
biological function of a diverse range of other proteins such as p53,[5] tubulin,[6] and Hsp90,[7] which are important 
therapeutic targets themselves. HDAC inhibitors (HDACi) have been shown to interfere with tumor angiogenesis, [2] and 
induce apoptosis in cancer stem cells.[8] HDACi have been suggested for cancer immunotherapy, due to their potent 
immunomodulatory activity both in tumour-bearing mice and cancer patients.[9]  
Metal complexes with their tunable 3D shape offer a unique opportunity to develop compounds for selective recognition 
and interaction with the active sites of proteins.[10] Recently, there has been an increased interest in the design of metal 
complexes that target histones[11] or epigenetic enzymes.[12] Metal-based HDACi include compounds based on Pt,[13] 
ReCp(CO)3,[14] ferrocene,[15] and Ru.[16]  
 
In our efforts to design multitargeted anticancer agents, i.e. a drug contains more than one pharmacophore in a single 
molecule,[17] the design concept of the organometallic HDACi presented here is based on a bioactive metal center, that 
can undergo ligand exchange reactions and form covalent bonds to target donor atoms; a vorinostat-inspired hydroxamic 
acid moiety as the Zn-binding group; and a 2-pyridinecarbothioamide (PCA) ligand. PCA-based organometallics were 
shown to interact selectively with plectin[18] and to have a preference for amino acid side chains over DNA, as shown in 
nucleosome core particle binding studies.[19] The high stability of PCA–metal bonds, even under acidic conditions, 
provides a structural scaffold suitable for oral administration.[19-20]  
The PCA-based hydroxamic acid ligands 3 and 4 were prepared in two steps (Scheme 1). Succinic or suberic anhydride 
were reacted with N-(4-aminophenyl)pyridine-2-carbothioamide to afford PCA-succinic acid 1 and PCA-suberic acid 2 in 
yields of 61 and 41%, respectively. PCAs 1 and 2 were converted into the respective hydroxamic acids 3 (29%) and 4 
(32%) with NH2OH, ethylchloroformate, and Et3N. This conversion was characterised by an upfield shift of the broad 
COOH singlet in the 1H NMR spectra from ca. 12 ppm in 1 and 2 to ca. 8.70 ppm for the hydroxyl protons in 3 and 4. X-
ray diffraction analysis of a single crystal of 1 showed that it crystallized in the orthorhombic space group Pbca (Table S1, 
Figure S1). The C6=S1 bond length of 1.665(3) Å was significantly longer than found for the carbonyl groups C13=O1 
and C15=O2 at 1.232(3) and 1.232(3) Å, respectively (Table S2). The aromatic rings are co-planar, stabilized by an 
intramolecular H bond between N1 of the pyridine ring and the amide HN2 (2.107 Å). The molecules form an expansive 
network of intermolecular H bonds that involve the carboxylic acid HO3 of one molecule and the carbonyl O2 of another 
(HO3···O2 distance of 2.669 Å; Figure S1). In addition, the amide proton HN3 and carbonyl oxygen form another set of 
intermolecular hydrogen bonds with an HN3···O1 distance of 2.085 Å. 
 
 
Scheme 1. Synthesis of the 2-pyridinecarbothioamide carboxylic (1 and 2) and hydroxamic acids (3 and 4) and their respective organometallic RuII 
(a), OsII (b), RhIII (c) and IrIII (d) complexes. 
Both the carboxylic (1 and 2) and hydroxamic (3 and 4) acid derivatives were converted to organometallics by reaction 
with the dimeric precursors [M(cym)Cl2]2 (M = Ru, Os; cym = η6-p-cymene) or [M(Cp*)Cl2]2 (M = Rh, Ir; Cp* = 
pentamethylcyclopentadienyl) in 37–75% yield. In the 1H NMR spectra, coordination of 1–4 to the metal ions caused 
deshielding of the pyridine proton H1 accompanied by downfield shifts of ca. 1 ppm depending on the metal center (δ = 
9.1–9.7 ppm). In contrast, H4, which is involved in a hydrogen bond with S1 in the crystal structure of 1, becomes more 
shielded and shifts upfield by ca. 0.2 ppm to around 8.5 ppm. 13C{1H} NMR spectroscopy confirmed the structural 
characterization, although not all of the C atoms were detectable. The compounds were also characterized by elemental 
analysis and electrospray ionization mass spectrometry (ESI-MS), all of which supported the identity of the compounds. 
The ESI-mass spectra of all complexes featured [M – 2Cl – H]+ ions as base peaks with the experimental m/z values and 
isotope distributions in close agreement to the calculated values. This shows the ease of deprotonation of the thioamide 
proton while in the solid state the amide remains protonated. This was confirmed by single crystal X-ray diffraction analysis 
of 1b (Table S1). Complex 1b crystallized in the monoclinic space group P21/c as two enantiomers and the structure 
featured the characteristic piano-stool configuration where the Os is coordinated to cym, the S,N-chelating PCA 1, and a 
chlorido ligand (Figure 1). The chloride counterion formed intermolecular H bonds with the amide proton HN3 and the 
thioamide proton HN2 to bridge two enantiomeric molecules of 1b (Figure S2). The Os−cymcentroid and the Os–Cl distances 
of 1.679(1) Å and 2.417(2) Å, respectively, were in a similar range as observed for structurally related [Os(cym)(PCA)Cl] 
complexes.[19] For coordination of the Os centre to S1 and N1, the H bond N1···HN2 for in 1 was broken. This resulted in 
the PCA ligand to lose its planarity (torsion angle C5–C6–N2–C7 135.08°) seen in the molecular structure of 1. Upon 
metal coordination, the bond C6–S1 was elongated (1.691(6) Å vs. 1.665(3) Å), as observed for related compounds.[19-20] 
This indicates higher single bond character for C6–S1 and higher double bond character for the C6–N2 bond.  
 
Figure 1. Molecular structure of one of the enantiomers of 1b drawn at 50% probability level. The counter ion and residual MeOH were removed 
for clarity. 
The stability of 4a–4d in D4-MeOD/D2O (4a and 4b) or D2O (4c and 4d) was studied by 1H NMR spectroscopy (Figures S3 
and S4). Compound 4c was remarkably soluble in water (47 mM), especially compared to 4d (0.6 mM). All complexes 
underwent chlorido/aqua ligand exchange, which was complete within 15 min for 4a, 4c and 4d and too fast to determine 
reaction kinetics for by NMR spectroscopy, while 4b reacted more slowly and the process took about 6 h. The formation 
of the aqua complexes was confirmed by addition of 2 eq. of AgNO3, which gave identical spectra (Figure S3). The aqua 
species were stable for at least 5 d. The ligand exchange appeared to be at least partly reversible in the presence of 104 
mM NaCl or 60 mM HCl, however, precipitation of probably the chlorido complex complicated data interpretation. The 
reversibility of the ligand exchange reaction was indicated, for example, in the case of 4c by a shift of the signal assigned 
to H1 from 8.41 ppm for the aqua species to 9.08 ppm for the chlorido complex in the 1H NMR spectra (Figure S3).  
Furthermore, 4a–4d were studied for their reactions with L-cysteine (Cys), L-methionine (Met), L-histidine (His), in 5% D4-
MeOD/D2O (4a and 4b) or D2O (4c and 4d) by 1H NMR spectroscopy (Figure S5). These experiments supported the 
results found in the stability studies. The compounds were highly stable and no adduct formation with His, Met or Cys 
was observed over 5 d. This level of stability of the compounds is remarkable, especially in presence of Cys, which has 
been reported to induce decomposition of Ru(arene) complexes.[19] 
The cytotoxicity of the PCAs 1–4 and their organometallic complexes was determined by the SRB assay in human 
colorectal (HCT116), non-small cell lung (H460), cervical (SiHa) and colon carcinoma (SW480) cells (Tables 1 and S3). 
Of the carboxylic acid derivatives and their complexes, only PCA 2 was moderately cytotoxic while for none of the 
complexes of 1 and 2 an IC50 value could be reached in the concentration range investigated. The hydroxamic acid 
derivatives 3 and 4 showed antiproliferative activity, especially the SAHA analogue 4, which gave IC50 values in the high 
nanomolar range (Table 1) and was at least 2 orders of magnitude more potent than its carboxylic acid derivative 2. This 
demonstrates the essential role of the hydroxamic acid functional group in the biological activity of many HDACi. Only the 
organometallic compounds formed with 4 showed cytotoxicity and their potency depended strongly on the metal fragment. 
Ru(cym) 4a and Os(cym) 4b were low to moderately cytotoxic, while the Cp* complexes of Rh 4c and Ir 4d showed the 
highest antiproliferative activity, with 4c being similarly cytotoxic as 4. To evaluate whether the redox chemistry of the 
metal center was the source of the difference in activity of 4a and 4c (Ru vs Rh), their ability to induce the formation of 
reactive oxygen species (ROS) was investigated but neither of the compounds showed higher ROS generation than the 
untreated control. 
 
Table 1. In vitro cytotoxic activity (mean IC50 values ± standard deviations) of PCA-hydroxamic acid 4 and its organometallic complexes 4a–4d in 
the human cancer cell lines HCT116 (colon), NCI-H460 (non-small cell lung), SiHa (cervix), and SW480 (colon) given in μM as determined by the 
SRB assay (exposure time 72 h). 
compound IC50 values (μM) 
HCT116 NCI-H460 SiHa SW480 
SAHA 0.46 ± 0.09 0.57 ± 0.01 1.6 ± 0.1 1.3 ± 0.07 
4 0.30 ± 0.14 0.98 ± 0.30 1.6 ± 0.6 1.5 ± 0.3 
4a 30 ± 3 120 ± 24 126 ± 15 124 ± 8 
4b 42 ± 5 136 ± 71 73 ± 5 170 ± 124 
4c 0.97 ± 0.10 3.5 ± 0.3 3.3 ± 0.1 3.3 ± 0.2 
4d 3.4 ± 0.5 11.4 ± 0.6 12 ± 0.3 11 ± 1 
 
Based on the cytotoxic data, 2–4 and 4a–4d were selected for screening of HDAC8 inhibition at a concentration of 10 
µM. The carboxylic acid 2 and the hydroxamic acid 3 showed very low activity at this concentration with residual HDAC8 
activity of 100 and 83%, respectively (Table S4). The presence of the hydroxamic acid in 3 proved beneficial with a slight 
inhibition of HDAC8 and this was confirmed for the SAHA derivative 4 with only 9% residual HDAC8 activity. This fact 
demonstrates the role of the length of the aliphatic chain which is required for the hydroxamic acid group to reach the Zn 
ion deep in the active site of the enzyme. Notably, all complexes of 4 were more potent than the ligand at this concentration 
and they were therefore included in a study to determine their IC50 values against HDAC1, HDAC6 and HDAC8 (Table 
2). PCA 4 and its organometallic compounds 4a–4d exhibited excellent HDAC inhibitory potential with IC50 values in the 
nM range, with coordination to organometallic moieties enhancing the HDAC1 and HDAC8 inhibitory activity of 4. The 
complexes were up to 10-fold more potent inhibitors of HDAC1 and HDAC8 than the clinically approved drug SAHA, while 
4 and its Rh(Cp*) complex 4c were 3-4 fold more potent inhibitors of HDAC6 compared to SAHA. In general, the 
organometallic compounds showed a slight selectivity for HDAC6, as would be expected given their structural similarity 
with SAHA, which was about an order of magnitude more potent against HDAC6 than HDAC1 and HDAC8 in this assay. 
The influence of the metal center may be explained by two effects. It can undergo ligand exchange reactions and despite 
not seeing adduct formation with isolated amino acids, the protein microenviroment may support interaction within the 
binding site of HDACs.[19] Moreover, the metal fragment can be considered as a bulky group that may form hydrophobic 
interactions or hydrogen bonds with aromatic amino acid side chains. [21] Comparison of the HDAC inhibitory and 
cytotoxicity data shows some correlation for HDAC6. In addition, the PCA ligand and the metal center may contribute to 
the biological activity through alternative pathways.  
 
Table 2. Inhibitory activity (IC50 in nM) of PCA-hydroxamic acid 4 and its organometallic complexes 4a–4d against 
HDAC1, HDAC6, and HDAC8 in comparison to SAHA. 
compound IC50 values (nM) 
HDAC1 HDAC6 HDAC8 
SAHA 301 ± 21 16 ± 1.5 840 ± 24 
4 458 ± 22 4 ± 1.5 759 ± 201 
4a 44 ± 24 15 ± 0.5 53 ± 11 
4b 45 ± 16 32 ± 11 99 ± 16 
4c 173 ± 30 5 ± 1 29 ± 6 
4d 67 ± 18 11 ± 0.6 29 ± 3 
 
The acetylation/deacetylation of histone proteins allows for the regulation of transcription. Removal of acetyl groups from 
histones by HDACs results in the suppression of transcription. SAHA is a potent HDAC inhibitor, in particular of HDAC6 
(Table 2), and was compared with the most active compounds 4 and 4c in terms of its potency to inhibit histone H3 
deacetylation in prostate carcinoma (PC3) cells (Figure 2) at concentrations of 1, 2 and 4 µM. Analysis of the 
immunblotting data for acetyl-H3 relative to β-tubulin suggests a concentration-dependent inhibitory potency for all three 
compounds, compared to the negative control, although only the data for SAHA was found to be statistically significant. 
SAHA was overall slightly more potent than 4 and 4c. 
 
Figure 2. Acetylation of histone variant H3 has been shown in response to SAHA, 4 and 4c at concentrations of 1, 2 and 4 µM in the PC3 cell line  
(n = 3). (A) Blot highlighting the differences in acetylation between different drugs, and (B) densitometry was used to quantify blots; **, *** and **** 
indicate p-values of <0.01, <0.001 and <0.0001. 
To understand the HDAC inhibitory activity of 4 and the two enantiomers of its complexes 4a–4d in comparison to SAHA, 
a molecular modelling approach was used in combination with molecular dynamics simulations. The active site of HDAC8 
consists of a long, narrow channel leading to a cavity that contains the catalytic machinery. The walls of the channel are 
formed by Tyr100, Tyr306, His180, Phe152, Gly151 and Met 274 and are primarily hydrophobic. [22] Studies with SAHA 
confirmed that the Zn2+ ion and also Tyr306 are the important active site components (Table S5).[15a, 22b] Upon modelling, 
4 and its enantiomeric metal complexes showed a good fit in the binding pocket as they superimposed SAHA and 
interacted with Zn through the hydroxamate motif (Figure S6 for 4bE2). In all cases, the metal fragments were sitting above 
the protein surface. With the exception of one of the enantiomers of 4c, the complexes formed H bonds with His180 (and 
the majority also with Asp101), while all but one of the enantiomers of 4b and 4 showed lipophilic contacts with Tyr100 
through the ligand backbone (Table S5). The latter fact may be of relevance when interpreting the HDAC inhibition data 
for 4 which was by far the least active HDAC8 inhibitor.  
Modelling the same compounds into HDAC6 resulted in similar observations as for HDAC8 with the compounds interacting 
with the Zn ion but the metal complexes were found lying in a nearby second channel as compared with SAHA and 4. 
This positioning supports additional interactions of the metal moiety with the protein through functionally important active 
site residues such as Tyr745, Pro464, Phe583, His463 and Gly473 (Figure 3 for 4cE2, Table S6).[23] Notably, the 
enantiomeric structures offer different binding options with amino acid side chains, most significantly His463 with its 
imidazole moiety, which may well undergo a ligand exchange reaction with one enantiomer, while the other has the labile 
chlorido ligand pointing away from it.  
 
Figure 3. The modelled configuration of 4cE2 in the binding site of HDAC6 (PDB ID 5eei). The complex is shown in the binding pocket with the 
protein surface rendered. Blue depicts a positive partial charge on the surface, red negative and grey neutral/lipophilic. 
The hemolytic activity of the most potent 4c to mouse red blood cells was assessed to gain further insight into its toxicity. 
At low concentrations similar to the IC50 values, 4c was not hemolytic. When the concentration was increased to 200 µM, 
4c showed about 10% hemolytic activity which was significantly lower toxicity than for example found for cisplatin which 
displays 100% hemolytic activity at this concentration.[24] 
The prognosis for patients with solid tumors is known to be angiogenesis-dependent.[25] HDACs, among many cellular 
functions, are closely linked to tumor angiogenesis, in particular under hypoxic environment.[2a] In pre-clinical animal 
models and clinical studies, the HDAC inhibitors SAHA and panobinostat have shown promising antiangiogenic activity.[26] 
Therefore, 4, 4c and for comparison SAHA were evaluated for their in vivo antiangiogenic activity in transgenic zebrafish 
at concentrations of 2 µM. Notably, the treatment of the zebrafish embryos with the Rh compound 4c substantially reduced 
the formation of new blood vessels in comparison to 4 and clinically used HDAC inhibitor SAHA (Figure 4).  
 
 
Figure 4. Confocal images of the developing trunk vasculature in 48 hpf (hours post fertilization) in fli1a:EGFP zebrafish embryos treated with either 
vehicle (DMSO) or 2 μM of either SAHA, 4 or 4c. (B) Schematic of a 48 hpf embryo showing the location of confocal images. (C) Quantitation of 
intersegmental vessel (ISV) formation at 48 hpf in treated embryos (n > 14 for all treatment groups). Embryos treated with 4c have impaired vascular 
development compared to the control. Scale bar = 100 µm. ** p<0.005 by Mann-Whitney test.  
Compounds 4 and 4c were evaluated for protein expression levels of vascular endothelial growth factor receptor 2 
(VEGFR2) and vascular endothelial growth factor A (VEGFA) in prostate carcinoma (PC3) cells using Western blotting. 
VEGFA is a cytokine that binds to VEGFR2, a tyrosine kinase receptor.[27] An insight into the regulation of these markers 
can provide information about the downstream pathways including protein kinase B (AKT), focal adhesion kinase (FAK) 
and proto-oncogene tyrosine-protein kinase (SRC) that in turn stimulate angiogenesis.[28] At all concentrations 
investigated, both 4 and 4c significantly reduced the expression of VEGFR2 as compared to the negative control after 
treatment for 24 h, while SAHA was shown to upregulate VEGFR2 at the same concentrations (Figure 5). This indicates 
a significant impact of the PCA moiety while there was hardly any difference between the PCA-derived ligand and its Rh 
complex.  
Both compounds showed slightly higher reductions in VEGFA compared to SAHA, however, without being statistically 
significant relative to the negative control (Figure S7). SAHA has been shown to induce sprouting of endothelial cell 
spheroids albeit at a higher concentration of 5 mM.[29] Reasons for this can be attributed to the differential effects of 
HDACs in different environments,[27b, 27c] and also HDACs can effect multiple gene expressions. 
 
 
Figure 5. VEGFR2 expression assessed as a percentage of β-tubulin in PC3 cells using Western blotting after 24 h. Data was quantified using 
densitometry. Concentrations of 1, 2 and 4 μM of 4 and 4c were compared with SAHA. Mean  SEM was plotted for each of the treatments; *, ** 
and *** indicate p-values of <0.05, <0.01 and <0.001, respectively compared to -ve control and was determined using parametric variant of Anova 
and multiple Tukey’s test (n = 3). 
In conclusion, we report an approach of combining different pharmacophores in a single molecule in an attempt to design 
potent anticancer agents targeting HDACs. To elucidate the role of each component of the target molecules, the bioactive 
PCA moiety was functionalized with hydroxamic and carboxylic acid residues and both the linker and metal fragment were 
varied. This led to the identification of PCA 4, which is structurally related to SAHA, and its Rh complex 4c as the most 
potent cytotoxins. While 4c was found to be highly cytotoxic, no hemolytic activity in mouse red blood cells was detected. 
Ligand 4 and its metal complexes showed a similar HDACi pattern as SAHA in HDAC1, HDAC6 and HDAC8 inhibition 
studies, which correlated to some extent with the cytotoxic activity but also suggested an impact of the other bioactive 
moieties beyond the SAHA-derived fragment on the biological activity. Zebrafish experiments suggested anti-angiogenic 
activity of the Rh complex 4c over that of 4, demonstrating the impact of the metal center. The reduction of VEGFR2 
expression supports this observation from the in vivo studies. This demonstrates that careful selection of bioactive 
moieties resulted in enhanced biological activity where each component of a single molecule has a special role to play in 
the search for new compounds with non-classical modes of action.  
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